Biosergen (Sweden) Performance
| BIOSGN Stock | 39.00 1.00 2.50% |
The firm shows a Beta (market volatility) of -0.0379, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biosergen are expected to decrease at a much lower rate. During the bear market, Biosergen is likely to outperform the market. At this point, Biosergen AS has a negative expected return of -0.37%. Please make sure to confirm Biosergen's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Biosergen AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Biosergen AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 589 K | |
| Free Cash Flow | -37.7 M |
Biosergen |
Biosergen Relative Risk vs. Return Landscape
If you would invest 5,060 in Biosergen AS on October 14, 2025 and sell it today you would lose (1,160) from holding Biosergen AS or give up 22.92% of portfolio value over 90 days. Biosergen AS is generating negative expected returns and assumes 3.8912% volatility on return distribution over the 90 days horizon. Simply put, 34% of stocks are less volatile than Biosergen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biosergen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biosergen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biosergen AS, and traders can use it to determine the average amount a Biosergen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0943
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIOSGN |
Estimated Market Risk
| 3.89 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biosergen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biosergen by adding Biosergen to a well-diversified portfolio.
Biosergen Fundamentals Growth
Biosergen Stock prices reflect investors' perceptions of the future prospects and financial health of Biosergen, and Biosergen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biosergen Stock performance.
| Operating Margin | (13.73) % | |||
| Current Valuation | 10.14 M | |||
| Shares Outstanding | 42.43 M | |||
| Price To Book | 6.55 X | |||
| Price To Sales | 16.05 X | |||
| EBITDA | (34.08 M) | |||
| Book Value Per Share | (0.28) X | |||
| Cash Flow From Operations | (45.3 M) | |||
| Earnings Per Share | (1.35) X | |||
| Total Asset | 29.49 M | |||
About Biosergen Performance
By analyzing Biosergen's fundamental ratios, stakeholders can gain valuable insights into Biosergen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biosergen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biosergen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Biosergen AS performance evaluation
Checking the ongoing alerts about Biosergen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biosergen AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biosergen AS generated a negative expected return over the last 90 days | |
| Biosergen AS has high historical volatility and very poor performance | |
| Biosergen AS has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.18 M) with loss before overhead, payroll, taxes, and interest of (213.6 K). | |
| Biosergen generates negative cash flow from operations |
- Analyzing Biosergen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biosergen's stock is overvalued or undervalued compared to its peers.
- Examining Biosergen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biosergen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biosergen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biosergen's stock. These opinions can provide insight into Biosergen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biosergen Stock analysis
When running Biosergen's price analysis, check to measure Biosergen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosergen is operating at the current time. Most of Biosergen's value examination focuses on studying past and present price action to predict the probability of Biosergen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosergen's price. Additionally, you may evaluate how the addition of Biosergen to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |